Key Insights
In Q4 2025, Abbott's diagnostics segment sales fell 2.5% year-over-year to $2.46 billion, missing estimates of $2.51 billion.
The nutrition segment experienced an 8.9% decline in sales to $1.94 billion, attributed to reduced volume and strategic price cuts.
Abbott's adjusted earnings per share for Q1 2026 are projected between $1.12 and $1.18, below analyst expectations of $1.20.
AI Analysis
Abbott Laboratories is expected to face continued challenges in the short term due to underperformance in its diagnostics and nutrition segments. Howe...
Market Outlook
Short-Term
In the immediate term, Abbott's stock is likely to remain under pressure due to the lowered profit forecast and analyst downgrades. Investors should monitor the company's ability to stabilize its diagnostics and nutrition segments.
Long-Term
Recent News
Continue your research
Keep researching Abbott Lowers Profit Forecast
Move from the topic summary into related coverage, article-level impact analysis, and the next scheduled catalyst.
Explore market intelligence
Connect this story to current themes across macro, equities, commodities, and risk.
Follow AI financial news
Find related coverage ranked around the assets and market themes you follow.
Analyze a market story
Review sentiment, relevance, likely impact, timeframe, confidence, and uncertainty.
Prepare for market events
Check scheduled catalysts and create event-specific email reminders with optional AI context.
Unlock the full Abbott Lowers Profit Forecast analysis
Get AI-powered insights, alerts, and market analysis for Abbott Lowers Profit Forecast and other topics you follow.
No credit card required